Mostrar el registro sencillo del ítem
dc.contributor.author | Pfeiffer, M.L. | |
dc.contributor.author | DuPont, H.L. | |
dc.contributor.author | Ochoa Woodell, Theresa Jean | |
dc.date.accessioned | 2022-01-18T19:26:47Z | |
dc.date.available | 2022-01-18T19:26:47Z | |
dc.date.issued | 2012 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12866/10875 | |
dc.description.abstract | Objectives: The etiologies, clinical presentations and diagnosis of acute pathogen-specific dysentery in children and adults in industrialized and developing regions is described to help develop recommendations for therapy. Methods: We conducted a systematic review of literature published between January 2000 and June to determine the frequency of occurrence of pathogen-specific dysentery. Results: Shigella, Salmonella, and Campylobacter remain the most frequent bacterial causes of dysentery worldwide. Shiga toxin-producing Escherichia coli (STEC) is potentially important in industrialized countries. Entamoeba histolytica must be considered in the developing world, particularly in rural or periurban areas. Clinicians should use epidemiological clues and knowledge of endemicity to suspect Vibrio spp., Aeromonas spp., Plesiomonas spp., Yersinia enterocolitica, Clostridium difficile, Cytomegalovirus or Schistosoma mansoni in cases presenting with dysentery. A single fecal sample studied for etiologic agents is the customary way to make an etiologic diagnosis. Conclusions: While a majority of dysenteric cases will not have an identifiable agent causing the illness, when an etiologic organism is identified, other than STEC, each has a specific recommended form of therapy, which is provided in this review. | en_US |
dc.language.iso | eng | |
dc.publisher | Elsevier | |
dc.relation.ispartofseries | Journal of Infection | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.subject | Humans | en_US |
dc.subject | Endemic Disease | en_US |
dc.subject | Rural Area | en_US |
dc.subject | Unclassified Drug | en_US |
dc.subject | Morbidity | en_US |
dc.subject | Incidence | en_US |
dc.subject | Developing Country | en_US |
dc.subject | Diarrhea | en_US |
dc.subject | Feces | en_US |
dc.subject | Ceftriaxone | en_US |
dc.subject | Vancomycin | en_US |
dc.subject | Acute Disease | en_US |
dc.subject | Systematic Review | en_US |
dc.subject | Urban Area | en_US |
dc.subject | Antimicrobial Therapy | en_US |
dc.subject | Computer Assisted Tomography | en_US |
dc.subject | Single Drug Dose | en_US |
dc.subject | Bacterial Infections | en_US |
dc.subject | Salmonella | en_US |
dc.subject | Feces Analysis | en_US |
dc.subject | Shigella | en_US |
dc.subject | Shigellosis | en_US |
dc.subject | Ciprofloxacin | en_US |
dc.subject | Quinoline Derived Antiinfective Agent | en_US |
dc.subject | Azithromycin | en_US |
dc.subject | Escherichia Coli Infection | en_US |
dc.subject | Microorganism Detection | en_US |
dc.subject | Metronidazole | en_US |
dc.subject | Paromomycin | en_US |
dc.subject | Aeromonas | en_US |
dc.subject | Lactoferrin | en_US |
dc.subject | Salmonellosis | en_US |
dc.subject | Erythromycin | en_US |
dc.subject | Schistosoma Mansoni | en_US |
dc.subject | Amebiasis | en_US |
dc.subject | Drug Sensitivity | en_US |
dc.subject | Cytomegalovirus | en_US |
dc.subject | Tinidazole | en_US |
dc.subject | Colonoscopy | en_US |
dc.subject | Shiga Toxin Producing Escherichia Coli | en_US |
dc.subject | Azithromycin | en_US |
dc.subject | Bacterial Infection | en_US |
dc.subject | Entamoeba Histolytica | en_US |
dc.subject | Campylobacter | en_US |
dc.subject | Aeromonas Infection | en_US |
dc.subject | Antiamebic Agent | en_US |
dc.subject | Campylobacteriosis | en_US |
dc.subject | Causal Attribution | en_US |
dc.subject | Clostridium Difficile | en_US |
dc.subject | Clostridium Difficile Infection | en_US |
dc.subject | Cytomegalovirus Infection | en_US |
dc.subject | Diiodohydroquine | en_US |
dc.subject | Dysentery | en_US |
dc.subject | E. Coli | en_US |
dc.subject | Fecal Leukocytes | en_US |
dc.subject | Infectious Colitis | en_US |
dc.subject | Intestinal Infections | en_US |
dc.subject | Leukocyte Count | en_US |
dc.subject | Plesiomonas Infection | en_US |
dc.subject | Schistosomiasis Mansoni | en_US |
dc.subject | Shiga Toxin Producing Escherichia Coli Infection | en_US |
dc.subject | Urtoxazumab | en_US |
dc.subject | Vibrio | en_US |
dc.subject | Vibriosis | en_US |
dc.subject | Yersinia Enterocolitica | en_US |
dc.subject | Yersiniosis | en_US |
dc.title | The patient presenting with acute dysentery - A systematic review | en_US |
dc.type | info:eu-repo/semantics/review | |
dc.identifier.doi | https://doi.org/10.1016/j.jinf.2012.01.006 | |
dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.03.08 | |
dc.relation.issn | 1532-2742 |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |